{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:20:23Z","timestamp":1778772023646,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:00:00Z","timestamp":1671235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the safety and efficacy of chemoradiotherapy or radiotherapy combined with nimotuzumab in the treatment of  unresectable oesophageal squamous cell carcinoma (ESCC) in elderly patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study retrospectively analysed 54 cases of elderly patients (aged over 70\u00a0years) with unresectable ESCC in our centre between December 2016 and November 2019. The patients were treated with a radiation dose of 50\u201361.6\u00a0Gy (25\u201330 fractions) combined with nimotuzumab for targeted therapy with or without chemotherapy according to each patient\u2019s condition. The patients were observed for quality of life, safety, side effects and survival before and after the treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 54 patients, 26 were treated with nimotuzumab combined with chemoradiotherapy\u00a0and 28 were treated with nimotuzumab combined with radiotherapy. Toxicities were mainly oesophagitis (\u2265\u2009Grade 2, 38.9%), myelosuppression (\u2265\u2009Grade 3, 24.1%) and hypoproteinaemia (any grade, 94.4%). The rates of\u00a0complete response, partial response, disease stability and disease progression were 11.1% (6\/54), 81.5% (44\/54), 3.7% (2\/54) and 3.7% (2\/54), respectively, and the overall objective response rate was 92.6% (50\/54). The median follow-up time was 35.1\u00a0months, and the 1- and 2-year overall survival (OS) and progression-free survival (PFS) rates were 61.1%\u00a0(1 year OS) and 35.2% (2 year\u00a0OS), 42.6% (1 year PFS) and 16.7% (2 year\u00a0PFS), respectively. The median OS and PFS rates were 16.0 and 10.0\u00a0months, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Nimotuzumab combined with chemoradiotherapy or radiotherapy was well tolerated in elderly patients with unresectable ESCC. This combination can achieve a good treatment response and enhance survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-022-02602-5","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:02:57Z","timestamp":1671292977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy analysis of chemoradiotherapy\/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,17]]},"reference":[{"issue":"6","key":"2602_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2602_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1007\/s11427-018-9461-5","volume":"62","author":"CC Wu","year":"2019","unstructured":"Wu CC, Li MN, Meng HB, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62(5):640\u20137. https:\/\/doi.org\/10.1007\/s11427-018-9461-5.","journal-title":"Sci China Life Sci"},{"issue":"5","key":"2602_CR3","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.1016\/S2214-109X(18)30127-X","volume":"6","author":"H Zeng","year":"2018","unstructured":"Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003\u201315: a pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 2018;6(5):e555\u201367. https:\/\/doi.org\/10.1016\/S2214-109X(18)30127-X.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2602_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bjc.6602625","volume":"93","author":"L Gibault","year":"2005","unstructured":"Gibault L, Metges JP, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93(1):107\u201315. https:\/\/doi.org\/10.1038\/sj.bjc.6602625.","journal-title":"Br J Cancer"},{"issue":"4","key":"2602_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3892\/ijo.2020.4981","volume":"56","author":"Y Yu","year":"2020","unstructured":"Yu Y, Guan H, Jiang LY, et al. Nimotuzumab, an EGFR targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma. Int J Oncol. 2020;56(4):945\u201356. https:\/\/doi.org\/10.3892\/ijo.2020.4981.","journal-title":"Int J Oncol"},{"issue":"3","key":"2602_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/cas.13481","volume":"109","author":"K Kato","year":"2018","unstructured":"Kato K, Ura T, Koizumi W, et al. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: a phase I study. Cancer Sci. 2018;109(3):785\u201393. https:\/\/doi.org\/10.1111\/cas.13481.","journal-title":"Cancer Sci"},{"key":"2602_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2017.10.005","volume":"88","author":"JG de Castro","year":"2018","unstructured":"de Castro JG, Segalla JG, de Azevedo SJ, et al. A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial. Eur J Cancer. 2018;88:21\u201330. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.005.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2602_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00280-019-03944-w","volume":"84","author":"SC Qi","year":"2019","unstructured":"Qi SC, Mao Y, Jiang MJ. A phase I study evaluating combined nimotuzumab and neoadjuvant chemoradiotherapy followed by surgery in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2019;84(5):1115\u201323. https:\/\/doi.org\/10.1007\/s00280-019-03944-w.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2602_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/15384047.2019.1598760","volume":"20","author":"W Jing","year":"2019","unstructured":"Jing W, Yan WW, Liu YG, et al. Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2019;20(8):1121\u20136. https:\/\/doi.org\/10.1080\/15384047.2019.1598760.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"2602_CR10","first-page":"497","volume":"20","author":"BD Minsky","year":"2006","unstructured":"Minsky BD. Primary combined-modality therapy for esophageal cancer. Oncology (Williston Park). 2006;20(5):497\u2013505 (discussion 505-6, 511-3).","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"2602_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21147\/j.issn.1000-9604.2021.01.06","volume":"33","author":"X Yang","year":"2021","unstructured":"Yang X, Zhai Y, Bi N, et al. Radiotherapy combined with nimotuzumab for elderly esophageal cancer patients: a phase II clinical trial. Chin J Cancer Res. 2021;33(1):53\u201360. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.01.06.","journal-title":"Chin J Cancer Res"},{"issue":"6","key":"2602_CR12","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000348383","volume":"84","author":"H Iwase","year":"2013","unstructured":"Iwase H, Shimada M, Tsuzuki T, et al. Concurrent chemoradiotherapy with a novel fluoropyrimidine, S-1, and cisplatin for locally advanced esophageal cancer: long-term results of a phase II trial. Oncology. 2013;84(6):342\u20139. https:\/\/doi.org\/10.1159\/000348383.","journal-title":"Oncology"},{"issue":"4","key":"2602_CR13","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2015.12.009","volume":"94","author":"LR Kleinberg","year":"2016","unstructured":"Kleinberg LR, Catalano PJ, Forastiere AA, et al. Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Randomized Phase 2 Trial of Neoadjuvant Preoperative Paclitaxel\/Cisplatin\/Radiation Therapy (RT) or Irinotecan\/Cisplatin\/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design. Int J Radiat Oncol Biol Phys. 2016;94(4):738\u201346. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.009.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2602_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10147-013-0564-3","volume":"19","author":"NY Ma","year":"2014","unstructured":"Ma NY, Cai XW, Fu XL, et al. Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. Int J Clin Oncol. 2014;19(2):297\u2013302. https:\/\/doi.org\/10.1007\/s10147-013-0564-3.","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"2602_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"5","key":"2602_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341\u20136. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2602_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"issue":"10","key":"2602_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox046","volume":"30","author":"Z Dai","year":"2017","unstructured":"Dai Z, Lang W, Yang H, et al. Validation of EORTC QLQ-OES18 for Chinese patients with esophageal cancer. Dis Esophagus. 2017;30(10):1\u20137. https:\/\/doi.org\/10.1093\/dote\/dox046.","journal-title":"Dis Esophagus"},{"issue":"10","key":"2602_CR19","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/s0959-8049(03)00270-3","volume":"39","author":"JM Blazeby","year":"2003","unstructured":"Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39(10):1384\u201394. https:\/\/doi.org\/10.1016\/s0959-8049(03)00270-3.","journal-title":"Eur J Cancer"},{"key":"2602_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/bs.acr.2019.05.004","volume":"144","author":"ZW Reichenbach","year":"2019","unstructured":"Reichenbach ZW, Murray MG, Saxena R, et al. Clinical and translational advances in esophageal squamous cell carcinoma. Adv Cancer Res. 2019;144:95\u2013135.","journal-title":"Adv Cancer Res"},{"issue":"2","key":"2602_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ijge.2013.08.008","volume":"8","author":"YS Leu","year":"2014","unstructured":"Leu YS, Chang YF, Lee JC, et al. Prognosis of Nasopharyngeal Carcinoma in the Elderly is Worse than in Younger Individuals-Experience of a Medical Institute. Int J Gerontol. 2014;8(2):81\u20134. https:\/\/doi.org\/10.1016\/j.ijge.2013.08.008.","journal-title":"Int J Gerontol"},{"issue":"4","key":"2602_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.ijge.2010.11.003","volume":"4","author":"HC Liu","year":"2010","unstructured":"Liu HC, Chen YC, Chen CH, et al. Esophagectomy in Elderly Patients With Esophageal Cancer. Int J Gerontol. 2010;4(4):176\u20139. https:\/\/doi.org\/10.1016\/j.ijge.2010.11.003.","journal-title":"Int J Gerontol"},{"issue":"8","key":"2602_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s11136-010-9675-8","volume":"19","author":"WC Chie","year":"2010","unstructured":"Chie WC, Tsai CJ, Chiang C, et al. Quality of life of patients with oesophageal cancer in Taiwan: validation and application of the Taiwan Chinese (Mandarin) version of the EORTC QLQ-OES18: a brief communication. Qual Life Res. 2010;19(8):1127\u201331. https:\/\/doi.org\/10.1007\/s11136-010-9675-8.","journal-title":"Qual Life Res"},{"issue":"15_suppl","key":"2602_CR24","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1200\/jco.2014.32.15_suppl.4078","volume":"32","author":"G Castro","year":"2014","unstructured":"Castro G, Skare NG, Andrade CJC, et al. Chemoradiation with or without nimotuzumab in locally advanced esophageal cancer (LAEC): a randomized phase II study (NICE trial). J Clin Oncol. 2014;32(15_suppl):4078. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.4078.","journal-title":"J Clin Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-022-02602-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-022-02602-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:03:09Z","timestamp":1671292989000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-022-02602-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,17]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2602"],"URL":"https:\/\/doi.org\/10.1186\/s12876-022-02602-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,17]]},"assertion":[{"value":"16 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Peking University International Hospital\/The Eighth Clinical Medical School. All patients in this study signed an informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"526"}}